AstraZeneca PLC (AZN)
75.19
+3.99
(+5.60%)
USD |
NASDAQ |
Apr 25, 13:21
AstraZeneca Cash from Investing (Quarterly): -1.077B for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -1.077B |
September 30, 2023 | -1.221B |
June 30, 2023 | -520.00M |
March 31, 2023 | -1.246B |
December 31, 2022 | -249.00M |
September 30, 2022 | -1.743B |
June 30, 2022 | -800.00M |
March 31, 2022 | -168.00M |
December 31, 2021 | -913.00M |
September 30, 2021 | -10.46B |
June 30, 2021 | -236.00M |
March 31, 2021 | 555.00M |
December 31, 2020 | 138.00M |
September 30, 2020 | -580.00M |
June 30, 2020 | 148.00M |
March 31, 2020 | 9.00M |
December 31, 2019 | 58.00M |
September 30, 2019 | 74.00M |
June 30, 2019 | -1.117B |
March 31, 2019 | 328.00M |
December 31, 2018 | 927.00M |
September 30, 2018 | -141.00M |
June 30, 2018 | -96.00M |
March 31, 2018 | 273.00M |
December 31, 2017 | -1.642B |
Date | Value |
---|---|
September 30, 2017 | -335.00M |
June 30, 2017 | -205.00M |
March 31, 2017 | -146.00M |
December 31, 2016 | 603.00M |
September 30, 2016 | -624.00M |
June 30, 2016 | -1.061B |
March 31, 2016 | -2.887B |
December 31, 2015 | -2.585B |
September 30, 2015 | -420.00M |
June 30, 2015 | -678.00M |
March 31, 2015 | -556.00M |
December 31, 2014 | -1.516B |
September 30, 2014 | -561.00M |
June 30, 2014 | -1.178B |
March 31, 2014 | -3.777B |
December 31, 2013 | -1.004B |
September 30, 2013 | -647.00M |
June 30, 2013 | -874.00M |
March 31, 2013 | -364.00M |
December 31, 2012 | -514.00M |
September 30, 2012 | -2.698B |
June 30, 2012 | 760.00M |
March 31, 2012 | 593.00M |
December 31, 2011 | -3.58B |
September 30, 2011 | 1.272B |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-10.46B
Minimum
Sep 2021
555.00M
Maximum
Mar 2021
-1.019B
Average
-520.00M
Median
Jun 2023
Cash from Investing (Quarterly) Benchmarks
GSK PLC | 374.35M |
Amgen Inc | -27.09B |
Sanofi SA | -- |
Viking Therapeutics Inc | 35.73M |
Fusion Pharmaceuticals Inc | -5.242M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | 2.38B |
Cash from Financing (Quarterly) | -291.00M |
Free Cash Flow | 6.567B |
Free Cash Flow Per Share (Quarterly) | 0.4573 |
Free Cash Flow to Equity (Quarterly) | 1.537B |
Free Cash Flow to Firm (Quarterly) | 1.801B |
Free Cash Flow Yield | 2.80% |